Product Description
For Diabetes Mellitus, Type 2 (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00475371)
Mechanisms of Action: GLP-1 Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Inhalant
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mannkind
Company Location: Eastern America
Company Founding Year: 1991
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00642538 |
MKC-253-002 | P1 |
Completed |
Type 2 Diabetes |
2008-09-01 |
2019-03-18 |
||
NCT00475371 |
MKC-253-001 | P1 |
Completed |
Type 2 Diabetes |
2007-06-01 |
2019-03-21 |
Treatments |
|
2007-003430-42 |
2007-003430-42 | P2 |
Completed |
Type 2 Diabetes |
2008-06-10 |
2022-03-12 |
Treatments |